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The use of orthopedic implants in joints has revolutionized the treatment of patients with
many debilitating chronic musculoskeletal diseases such as osteoarthritis. However, the
introduction of foreign material into the human body predisposes the body to infection.The
treatment of these infections has become very complicated since the orthopedic implants
serve as a surface for multiple species of bacteria to grow at a time into a resistant biofilm
layer.This biofilm layer serves as a protectant for the bacterial colonies on the implant mak-
ing them more resistant and difficult to eradicate when using standard antibiotic treatment.
In some cases, the use of antibiotics alone has even made the bacteria more resistant to
treatment. Thus, there has been surge in the creation of non-antibiotic anti-biofilm agents
to help disrupt the biofilms on the orthopedic implants to help eliminate the infections. In
this study, we discuss infections of orthopedic implants in the shoulder then we review the
main categories of anti-biofilm agents that have been used for the treatment of infections
on orthopedic implants. Then, we introduce some of the newer biofilm disrupting technol-
ogy that has been studied in the past few years that may advance the treatment options
for orthopedic implants in the future.
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Implants have become an indispensable part of orthopedic medi-
cine. The use of orthopedic implants has revolutionized the treat-
ment of patients with debilitating diseases like osteoarthritis and
bone fractures. However, the compromise of the skin barrier dur-
ing surgical procedures and the introduction of foreign material
during joint replacement may predispose the body to infection,
including biofilm creating bacteria.
A biofilm is an assemblage of surface-associated microbial cells
that is enclosed in an extracellular polymeric substance (EPS)
matrix (1). Biofilms are enhanced by the ability of bacteria to
attach to an orthopedic implant through their surface structures
such as pili, fimbriae, flagella, and glycocalyx (2). Additionally,
adherence of microorganisms to the surface of the implant may
involve non-specific factors like surface tension, hydrophobicity,
and electrostatic forces (1). In general, any surface is susceptible to
biofilm growth, but rougher and more hydrophobic surfaces will
accumulate biofilms more rapidly (3). These bacterial biofilms can
grow to reach thicknesses of 100 mm (4). The depletion of nutri-
ents that can easily occur at the implant surface results in a slow
growing stationary state that can render the biofilm up to 1000
times more resistant to most antimicrobial agents when compared
to the single bacteria cell (4). Eradicating these complicated slow
growing biofilms with antibiotic therapy alone becomes extremely
difficult. Prosthetic joint biofilms can be mono- or polymicrobial
and are frequently caused by Staphylococcus aureus, coagulase-
negative Staphylococci, beta-hemolytic Streptococci, and aero-
bic Gram negative rods (including Pseudomonas aeruginosa) (5)
Moreover, the timeline of the biofilm formation has proven to
be critical to its susceptibility to antibiotics (6). In other words,
within the first week of formation, a biofilm might be susceptible
to tobramycin and piperacillin and subsequently become resistant
(6). Treatment with only antibiotics can increase the resistance of
these infections and there have even been cases where they have
stimulated the growth of the biofilms (7, 8).
The development of these complicated infections after ortho-
pedic implant surgery is a major problem. There are about one
million joint replacements, hip, knee, and shoulder (9, 10), per-
formed each year in the United States, which is expected to exceed
four million by 2030 (11, 12). Infection rates for hip, knee, and
shoulder arthroplasty at most centers are reported to be <2%,
with most of these occurring in the first 2 years post-op (4, 8, 11,
13). One and two-stage revision can serve as definitive treatment
and success rates have been documented in case-series to be 80
and 90%, respectively (14–17). Additionally, aggressive debride-
ment and retention of the implant is an option in select cases of
early-onset infection (30 days after implant) with no evidence of
loosening or sinus tract formation (18). This strategy in early-
onset infection may be curative in combination with long-term
antibiotics in up to 71% of cases (19–21). Finally, resection without
reimplantation is a last resort (16). However, the cost and morbid-
ity of periprosthetic joint infections and revision joint arthroplasty
can be exorbitant (22). Conservative estimates suggest that each
prosthetic joint infection may cost $50,000 or more (23), and the
total economic burden of these prosthetic joint infections will only
continue to increase with the number of total joint arthroplasties
performed every year (13, 22). That is why it is imperative that
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we continue to pursue other methods besides antibiotics to help
prevent and treat biofilm-forming infections. We will review the
different types of technology that have been developed to deter
biofilm formation and introduce some of the newer interventions
being researched to combat these infections.
Modification of the orthopedic implants is one of the first
aspects looked at in preventing these infections. The type of alloy
used in implants has been the focus of many research studies.
When testing the ability of some of the more common bacte-
ria in implant infections such as the Staphylococcus spp., it was
found that the bacteria had decreased ability to adhere and create
a biofilm layer on titanium than stainless steel or polymethyl-
methacrylate (24). This can be explained by the ability of titanium
to keep the bacteria dispersed on the implant surface making the
bacteria more susceptible to antibiotics (25). This antimicrobial
effect is one reason why titanium alloy has become one of the more
popular alloy used in orthopedic implants. A recent study looked
at innovations using titanium alloy investigating vanadium free
titanium alloys. They found this specialized alloy had decreased
bacterial adherence and biofilm formation than titanium that
contains vanadium (26).
The field of anti-biofilm agents has been increasing dramati-
cally and there is an exhaustive list of agents in each category of
this field as described in Campoccia et al. (27). Agents that have
bacteria repelling and anti-adhesive surfaces target the factors that
enhance adhesion of the bacteria to the orthopedic implant that
are ubiquitous to the common infecting bacteria (27). These anti-
biofilm agents utilize hydrophilic, highly hydrated, and anionic
surfaces that are typically most difficult for bacteria to adhere to
(27). Polyethylene oxide is an example of this category that can
be applied to a synthetic surface such as an orthopedic implant
to prevent bacterial attachment and biofilm development (28).
While most anti-biofilm surface repelling agents use hydrophilic
properties, there is also a recent example of an agent that uses a
hydrophobic polycationic surface on titanium and stainless steel
implants. These were found to inhibit biofilm formation and also
enhance bone healing in an infectious environment (29).
Another category of anti-biofilm agents are intrinsically bioac-
tive materials that are non-antibiotic compounds with innate
antibacterial properties in their structure. Examples in this cat-
egory are metals such as silver and copper. The antibacterial
properties of the metals come from their corrosive properties that
result in ion release that can disrupt essential processes of the bac-
teria such as those in the respiratory chain (27). These metals can
be integrated onto the surface of an orthopedic implant to prevent
adhesion of the bacteria.
There are many examples of bioactive antibacterial coatings
that are placed on top of an implant surface that have active
antibacterial properties. One example of this is when the implant
surface is cross-linked with a bioactive molecule such as human
b-defensin-3. Recent studies on the antimicrobial peptide human
b-defensin-3 show that it has the capacity to reduce the number
of bacterial colonies that accumulate on titanium surfaces and
can be effective against resistant organisms such as methicillin-
resistant Staphylococcus epidermidis (MRSE) and methicillin-
resistant Staphylococcus aureus (MRSA) (30, 31). Another type
of bioactive antibacterial coating releases nitric oxide that can
combine with superoxide to produce peroxynitrite, which has
very cytotoxic actions against bacteria (27). Polymer coatings-
containing diazeniumdiolates are an example of a nitric-oxide
releasing coating (27, 32). Along the same line are reactive oxygen
species-releasing coatings such as polycaprolactone incorporating
calcium peroxide (27). Studies have shown that bursts of calcium
peroxide can be bactericidal while only having short term toxic
effects to surrounding host tissues (33). There are also photoac-
tivated bioactive biomaterials that can be activated at certain UV
wavelength to exhibit their bactericidal effects such as the anatase
TiO2, which is activated at the 385 nm UV wavelength (27).
Another category is nanostructured biomaterials that contain
compounds such as silver or chitosan that have antibacterial prop-
erties (27). The nanostructures can also be used to alter the surface
functionality (solubility, surface charge, and other properties) of
the implant making it more difficult for bacteria to attach (27, 34).
Research is being focused on the use of vaccines against bacteria
that commonly infect implants. These vaccines contain polysac-
charide or protein from the bacterial surface. When they are
administered, the body develops immunoglobins against these
bacterial proteins or polysaccharides to prevent the biofilm forma-
tion (34). Most attempts at developing a vaccine against Staphylo-
coccus aureus have been largely unsuccessful due to the adaptability
and phenotypic variation exhibited by this bacteria (35). One
example that showed promise was the StaphVAX against Staphy-
lococcus aureus capsular polysaccharides. StaphVAX successfully
made it to phase III clinical trials, but was withdrawn when the
vaccine’s effectiveness in producing the immunoglobins against
the bacteria decreased to <30% in the year (36). A recently devel-
oped quadrivalent vaccine against Staphylococcus aureus (targeting
glucosaminidase, an ABC transporter lipoprotein, a conserved
hypothetical protein, and a conserved lipoprotein) was able to
clear 87.5% of the bacterial biofilm infections in combination with
antibiotics compared to 22% in those just given with the vaccine
(37). This shows the importance of combining vaccine and antibi-
otic treatment with this therapy if it becomes successful clinically
in the future.
The use of bacteriophages, which are viruses that infect and
destroy bacteria, have recently been explored for their effects to
remove biofilms in orthopedic implants. One study found that
bacteriophages enhanced the effects of antibiotics in eliminat-
ing orthopedic implant infections of MRSA and Pseudomonas
aeruginosa in rat models (38).
Bioactive enzymes lyse certain elements of the biofilm aggre-
gating on the orthopedic implant resulting in the destruction of
the biofilm. For example, dispersin B, which lyses polymers or
Proteinase K, which lyses proteins of the biofilm structure both
of which make the bacteria more susceptible to antibiotic treat-
ment (27). A number of cytotoxic agents have also been found
to be successful in removing biofilms from implant surfaces. In a
recent review, the most successful cytotoxic agent found to elimi-
nate biofilms on titanium surfaces was citric acid (39). While there
is limited literature on these agents, they show promise and more
studies are needed to fully understand their efficacy.
Another new field being researched is the use of electrical stim-
ulation on orthopedic implant surfaces. Studies have shown that
when an electrical current was applied to a stainless steel implant
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infected with Staphylococcus aureus and Staphylococcus epidermis,
the current was able to enhance detachment of the biofilm (40–42).
One of these studies tested the use of an electric current in vivo with
rabbit models that had an external power source that was attached
to an infected stainless steel implants that provided a current. They
found this model to be successful in reducing the biofilm load (41).
Applying an electrical current to infected implants in combination
with antibiotic therapy could be favorable treatment algorithm in
the future so that patients could avoid having to go through major
single-stage revision or two-stage reimplantation procedures.
Another potential innovation applied pulsed electromagnetic
fields to stainless steel pegs infected with biofilms of Staphylococ-
cus epidermis in combination with antibiotics. This study reported
a 50% decrease in the minimum biofilm inhibitory concentra-
tion needed for gentamicin; however, this effect was not seen with
vancomycin (43).
A new surge in research has been in the use of laser-generated
shockwaves, which use mechanical energy to break up biofilms
(35). One study found that around 97.9% of Pseudomonas aerug-
inosa biofilms on nitinol stents could be removed with just 4–10 s
of applying the laser (44). Laser-generated shockwaves were able to
break up the biofilm layer into bacteria in its single-celled plank-
tonic form that can be more easily treated with antibiotics (44).
We can no longer rely solely on antibiotics and surgery to treat
these infections because of the increased patient costs and mor-
bidity. In addition, the current treatment algorithms are becoming
increasingly less effective with more virulent organisms and bacte-
rial resistance. The application of various technologies and differ-
ent disciplines can advance the field of biofilm disrupting technol-
ogy. Innovative biofilm-disrupting-treatments are at the forefront
of medical research as scientists continue to look for new technol-
ogy to combat the complicated bacteria that infect implants.
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